Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04. September 2024 16:05 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences to Participate at Upcoming Investor Conferences
04. September 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates
13. August 2024 16:08 ET
|
Solid Biosciences Inc.
– Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4...
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05. August 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01. Juli 2024 16:19 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences Joins the Russell 3000® Index
01. Juli 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04. Juni 2024 16:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
15. Mai 2024 07:52 ET
|
Solid Biosciences Inc.
— Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trialexpected Q2 2024 — —...
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting
07. Mai 2024 07:00 ET
|
Solid Biosciences Inc.
— Presentations to highlight AAV manufacturing and purification improvements, vector biology updates,and a comprehensive non-clinical data overview of the company’s lead SGT-003 program — ...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02. Mai 2024 16:05 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...